23,048 Shares in Harrow, Inc. (NASDAQ:HROW) Purchased by Harvest Investment Services LLC

Harvest Investment Services LLC purchased a new stake in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 23,048 shares of the company's stock, valued at approximately $773,000. Harvest Investment Services LLC owned 0.06% of Harrow at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Tower Research Capital LLC TRC grew its stake in shares of Harrow by 769.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after acquiring an additional 1,462 shares during the last quarter. AlphaQuest LLC raised its holdings in Harrow by 452.8% in the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock worth $118,000 after buying an additional 2,889 shares during the last quarter. Federated Hermes Inc. bought a new position in shares of Harrow in the fourth quarter worth approximately $214,000. Maridea Wealth Management LLC purchased a new stake in shares of Harrow during the fourth quarter valued at approximately $222,000. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Harrow during the fourth quarter valued at approximately $235,000. Institutional investors own 72.76% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on HROW. B. Riley reduced their target price on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. HC Wainwright reiterated a "buy" rating and set a $57.00 target price on shares of Harrow in a research note on Monday, March 31st.

Harrow Stock Performance

NASDAQ HROW opened at $22.91 on Wednesday. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. Harrow, Inc. has a twelve month low of $9.86 and a twelve month high of $59.23. The business has a 50-day moving average price of $25.81 and a 200-day moving average price of $35.26. The firm has a market cap of $816.83 million, a price-to-earnings ratio of -24.37 and a beta of 0.46.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings data on Thursday, March 27th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.11 by $0.14. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The business had revenue of $66.83 million during the quarter, compared to analyst estimates of $66.01 million. As a group, equities research analysts predict that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Want to see what other hedge funds are holding HROW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harrow, Inc. (NASDAQ:HROW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.